GSK Gets 2nd Chance To Argue Preemption In Zofran MDL

By Chris Villani (July 10, 2019, 5:24 PM EDT) -- A Massachusetts federal judge on Wednesday said GlaxoSmithKline will get another chance to argue that claims its anti-nausea drug Zofran caused birth defects are federally preempted, adding he will seek guidance from the FDA after a landmark high court ruling put the preemption question in his hands.

In a hearing, U.S. District Judge F. Dennis Saylor IV said he had no choice but to delay the first bellwether trial in the multidistrict litigation consolidated in Massachusetts in 2015 and to vacate parts of his February ruling denying summary judgment for GSK.

About three months after Judge Saylor's ruling, which would have...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!